Literature DB >> 2117180

Aerosol therapy in AIDS.

S P Newman1, A K Simonds.   

Abstract

Pneumocystis carinii pneumonia (PCP) is the most common presenting symptom in patients with the acquired immunodeficiency syndrome (AIDS). Clinical trials have shown that inhaled pentamidine, delivered by nebulizer, is an effective prophylaxis for PCP in high-risk patients, and can be used to treat mild to moderate episodes. Side effects are minor, in marked contrast to the parenteral route of administration. The choice of nebulizer system will determine both alveolar delivery of pentamidine and the incidence of cough related to deposition of droplets on large conducting airways. Radioaerosol studies have suggested that optimum nebulizer systems for inhaled pentamidine deliver the majority of the aerosol mass in droplets smaller than 2 microns diameter, ideal for alveolar penetration.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2117180     DOI: 10.1007/bf02718195

Source DB:  PubMed          Journal:  Lung        ISSN: 0341-2040            Impact factor:   2.584


  12 in total

1.  Differences in relative efficiency of nebulisers for pentamidine administration.

Authors:  M J O'Doherty; S Thomas; C Page; D Barlow; C Bradbeer; T O Nunan; N T Bateman
Journal:  Lancet       Date:  1988-12-03       Impact factor: 79.321

2.  Aerosolised pentamidine.

Authors:  A K Simonds; S P Newman; M A Johnson; N Talaee; C A Lee; S W Clarke
Journal:  Lancet       Date:  1989-01-28       Impact factor: 79.321

3.  Prevention of Pneumocystis carinii pneumonia by inhaled pentamidine.

Authors:  J A Golden; D Chernoff; H Hollander; D Feigal; J E Conte
Journal:  Lancet       Date:  1989-03-25       Impact factor: 79.321

4.  Nebulised pentamidine as treatment for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome.

Authors:  R F Miller; P Godfrey-Faussett; S J Semple
Journal:  Thorax       Date:  1989-07       Impact factor: 9.139

5.  Aerosolized pentamidine as second line therapy in patients with AIDS and Pneumocystis carinii pneumonia.

Authors:  A B Montgomery; R J Debs; J M Luce; K J Corkery; J Turner; P C Hopewell
Journal:  Chest       Date:  1989-04       Impact factor: 9.410

Review 6.  Treatable aspects of infection due to human immunodeficiency virus.

Authors:  L S Young
Journal:  Lancet       Date:  1987-12-26       Impact factor: 79.321

7.  Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial.

Authors:  J M Wharton; D L Coleman; C B Wofsy; J M Luce; W Blumenfeld; W K Hadley; L Ingram-Drake; P A Volberding; P C Hopewell
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

8.  Aerosolised pentamidine as sole therapy for Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome.

Authors:  A B Montgomery; R J Debs; J M Luce; K J Corkery; J Turner; E N Brunette; E T Lin; P C Hopewell
Journal:  Lancet       Date:  1987-08-29       Impact factor: 79.321

9.  Selective delivery of pentamidine to the lung by aerosol.

Authors:  A B Montgomery; R J Debs; J M Luce; K J Corkery; J Turner; E N Brunette; E T Lin; P C Hopewell
Journal:  Am Rev Respir Dis       Date:  1988-02

10.  Droplet size distributions of nebulised aerosols for inhalation therapy.

Authors:  S P Newman; P G Pellow; S W Clarke
Journal:  Clin Phys Physiol Meas       Date:  1986-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.